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Quantitative Phosphoproteomics of Cytotoxic T
Cells to Reveal Protein Kinase D 2 Regulated
Networks*□S
María N. Navarro‡¶, Juergen Goebel‡, Jens L. Hukelmann‡, and Doreen A. Cantrell‡§
The focus of the present study was to characterize the
phosphoproteome of cytotoxic T cells and to explore the
role of the serine threonine kinase PKD2 (Protein Kinase
D2) in the phosphorylation networks of this key lympho-
cyte population. We used Stable Isotope Labeling of
Amino acids in Culture (SILAC) combined with phospho-
peptide enrichment and quantitative mass-spectrometry
to determine the impact of PKD2 loss on the cytotoxic T
cells phosphoproteome. We identified 15,871 phosphory-
lations on 3505 proteins in cytotoxic T cells. 450 phospho-
sites on 281 proteins were down-regulated and 300 phos-
phosites on 196 proteins were up-regulated in PKD2 null
cytotoxic T cells. These data give valuable new insights
about the protein phosphorylation networks operational
in effector T cells and reveal that PKD2 regulates directly
and indirectly about 5% of the cytotoxic T-cell phospho-
proteome. PKD2 candidate substrates identified in this
study include proteins involved in two distinct biological
functions: regulation of protein sorting and intracellular
vesicle trafficking, and control of chromatin structure,
transcription, and translation. In other cell types, PKD
substrates include class II histone deacetylases such as
HDAC7 and actin regulatory proteins such as Slingshot.
The current data show these are not PKD substrates in
primary T cells revealing that the functional role of PKD
isoforms is different in different cell lineages. Molecular
& Cellular Proteomics 13: 10.1074/mcp.M113.037242,
3544–3557, 2014.
The mammalian serine/threonine protein kinase D (PKD)1
family comprises three different but closely related serine
kinases, PKD1, PKD2, and PKD3 all of which have a highly
conserved N-terminal regulatory domain containing two cys-
teine-rich diacylglycerol (DAG) binding domains (1). T lympho-
cytes express high levels of PKD2 and this kinase is selec-
tively activated by the T-cell antigen receptor (TCR). The
activation of PKD2 is initiated by DAG binding to the PKD N
terminus but is also critically dependent on Protein kinase C
(PKC)-mediated phosphorylation of two serine residues
(Ser707 and Ser711) within the activation loop of the PKD2
catalytic domain (2, 3). The importance of PKD2 for T-cell
function has been probed by experiments in mice that lack
expression of catalytically active PKD2. These studies have
shown that PKD2 is important for effector cytokine production
after T-cell antigen receptor engagement and also for optimal
induction of T-cell dependent antibody responses (4, 5). PKD2
thus has a key role in adult mice to control the function of T
cells during adaptive immune responses.
The importance of PKD2 for primary T-cell function makes
it critical to understand how PKD2 controls protein phosphor-
ylation pathways. In this context, experiments with constitu-
tively active and dominant negative PKD mutants in tissue
culture cell lines have identified a number of candidate PKD
substrates. These include the protein phosphatase Slingshot
(6, 7), the Ras effector Rin1 (8), phosphatidylinositol-4 kinase
III beta (9), lipid and sterol transfer proteins such as CERT and
OSBP (10, 11). There are also experiments that have identified
a key role for PKDs in regulating the phosphorylation and
subcellular localization of the class II histone deacetylases
(HDACs). For example, in PKD null DT40 B cell lymphoma
cells the B cell antigen receptor cannot induce the phosphor-
ylation and nuclear exclusion of the class II HDACs, HDAC5
and 7 (12). However, it remains to be determined whether the
documented PKD substrates are universal PKD substrates in
different cell lineages. In this context, the intracellular local-
ization of PKD isoforms varies in different cells (13), and PKDs
have also been shown to traffic between different cellular
locations in response to specific stimuli (2, 14). PKD function
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is dependent on its localization and cell context presumably
reflecting that the localization of PKDs plays a key role deter-
mining the nature of PKD substrates in different cell popula-
tions (15).
Recently, mass-spectrometry based quantitative phospho-
proteomics has been used to explore serine/threonine kinase
controlled signaling pathways in T cells (16–18). In this regard,
SILAC labeling combined with quantitative mass-spectrome-
try has recently been used to examine the impact of overex-
pressing active and/or kinase dead PKD1 mutants in HEK293
cells treated with nocodazole, a microtubule-depolymerizing
reagent that disrupts the Golgi complex and activates PKD1
(19). This has identified a number of PKD1 substrates in
HEK293 cells. PKD1 and PKD2 are highly homologous ki-
nases but it remains to be determined whether the PKD1
substrates identified in nocodazole-treated HEK293 cells are
relevant to signaling pathways controlled by endogenous
PKD2 in antigen receptor activated primary T cells.
Accordingly, in the present study we used SILAC labeling
combined with phosphopeptide enrichment and mass-spec-
trometry quantification to compare the phosphoproteome of
antigen receptor activated wild type and PKD2 deficient cy-
totoxic T cells (CTLs). Our experiments identify and quantify
more than 15,000 site-specific phosphorylations in antigen
receptor activated CTLs and thus provide a unique data
source about the signaling networks operational in these
cells. The loss of PKD2 impacts on about 5% of these phos-
phorylations and reveals that PKD2 has both positive and
negative regulatory roles in regulating protein phosphorylation
networks in T cells.
EXPERIMENTAL PROCEDURES
Mice, Cell Culture, and SILAC Labeling—P14 T-cell receptor trans-
genic mice (P14-TCR) PKD2 null mice (4, 5), and wild-type littermates
were bred and maintained under specific pathogen-free conditions in
the Wellcome Trust Biocenter at the University of Dundee in compli-
ance with U.K. Home Office Animals (Scientific Procedures) Act 1986
guidelines as previously describe (17, 20). P14 CTL were generated
and labeled in SILAC media as previously described (17). Briefly,
splenocytes were activated for 2 days with the P14-TCR cognate
ligand (peptide gp33–41 from Lymphocytic Choriomeningitis Virus,
LCMV). Then, cells were cultured for 4 days in SILAC medium
(Dundee Cell Products, Dundee, UK), L-proline 200 mg/l, L-arginine 84
mg/l, pre-supplemented with 300 mg/l L-glutamate, 10% dialyzed
FCS with a 10kDa cutoff (Invitrogen, Carlsbad, CA), 50 units/ml pen-
icillin-G, 50 g/ml streptomycin and 50 M -mercaptoethanol, and
20 ng/ml IL-2 (Proleukin, Novartis, Basel, Switzerland). The following
arginine and lysine isotopes were used:
R0K0 (light): L  [12C6, 14N4] arginine (R0)
and L  [12C6, 14N2] lysine (K0)
R10K8 (heavy): L  [13C6, 15N4] arginine (R10)
and L  [13C6, 15N2] lysine (K8)
The SILAC labeling was performed in three biological repli-
cates, where the P14 wild-type CTLs cells comprised the
“light” condition and PKD2 null CTLs were labeled with
“heavy” amino acids in two experiments (experiments 1 and
2), and a label switch was performed in the third experiment
(experiment 3).
For the generation of non-TCR transgenic CTLs, spleno-
cytes were activated for 2 days with 0.5 g/ml of anti-CD3
antibody (2C11, R&D Systems, Minneapolis, MN), followed by
4 days of culture in RPMI (Life Technologies), 10% FCS
(Invitrogen), supplemented with penicillin-G, streptomycin,
-mercaptoethanol, and IL-2.
Sample Preparation, Phosphopeptide Enrichment, and Mass Spec-
trometry—P14 wild-type and PKD2 null CTLs differentially labeled in
SILAC media for 4 days were mixed at 1:1 ratio (total 3  108 cells)
and stimulated for 5 min with P14-TCR cognate peptide (LCMV
gp33–41). After TCR stimulation, cells were washed once in cold PBS
and were subjected to cytosol and nuclear fractionation as previously
described (17). Briefly, cells were resuspended in hypotonic lysis
buffer (10 mM HEPES, pH 7.9, 15 mM KCl, 4 mM MgCl2, 0.1 mM EDTA,
10 mM NaF, 0.15% (v/v) Nonidet-P40, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na3VO4, and 1 mM dithiothreitol) and centrifuged for 1
min at 10,000  g. Cytosolic fractions were removed and nuclear-
membrane fractions were resuspended in nuclear lysis buffer (10 mM
Tris, pH 7.05, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM
NaF, 5 mM ZnCl2, 10% (v/v) glycerol, and 0.5% (v/v) Triton-X100).
Cytosolic and nuclear fractions were precipitated with trichloroacetic
acid (10%, v/v) for 15 min/ice. Protein pellets were resuspended in
Urea 8 M Tris-HCl 100 mM. Cytosolic and nuclear lysates were sub-
jected to alkylation with iodoacetamide prior to trypsin digestion
(Roche, Basel, Switzerland).
Hydrophilic Liquid Interaction Chromatography (HILIC), Immobi-
lized Metal Ion Affinity Chromatography (IMAC), and Titanium Dioxide
(TiO2) Affinity Chromatography—Proteolytic digestion products were
desalted on a 1-g Sep-Pak cartridge (Waters, Milford, MA), and
subjected to hydrophilic interaction liquid chromatography (HILIC)
using a 4.6  250-mm TSKgel Amide-80 5-m particle column
(Tosoh Biosciences, Tokyo, Japan). The following buffers were used:
HILIC buffer A (0.1% TFA) and HILIC buffer B (99.9% acetonitrile and
0.1% TFA). The peptide pellets were resuspended in 80% HILIC
buffer B and injected onto the HILIC column. The chromatography
was done using the following elution gradient: 80% B held for 20 min
followed by 80% B to 60% B in 40 min and finally 0% B for 10 min.
Eighteen fractions of each subcellular compartment were collected
throughout the gradient and further enriched in phosphopeptides by
immobilized metal affinity chromatography (IMAC, Phos-Select,
Sigma) following manufacturer’s instructions. Peptides were eluted
with 200 l, 0.4 M NH4OH followed with 200 l, 0.2 M NH4OH/50%
acetonitrile. A gel-loading tip was used to remove elution fractions
and further remaining IMAC beads were removed by passing frac-
tions through a ZipTip (Millipore). The supernatants from the IMAC
(combining the 18 fractions for each subcellular compartment in nine
samples) were used for additional TiO2 pull down (Titanspheres, GL
Sciences, Shinjuku, Japan).
Liquid Chromatography - Mass Spectrometry (LC-MS)—The pep-
tide mixture was separated by nanoscale C18 reverse-phase liquid
chromatography (Ultimate 3000 nLC (Dionex, Sunnyvale, CA) coupled
online to a Linear Trap Quadrupole (LTQ)-Orbitrap mass spectrometer
(LTQ-Orbitrap Velos; Thermo Fisher Scientific). The following buffers
were used: HPLC Buffer A (2% acetonitrile and 0.01% formic acid),
HPLC Buffer B (90% acetonitrile and 0.08% formic acid) and HPLC
Buffer C (0.05% trifluoroacetic acid). Samples were injected in 1%
formic acid, washed onto the column with HPLC Buffer C and eluted
with a flow of 0.3 l/min under usage of the following buffer gradient:
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5% B (0–3 min), 5–35% B (3–68 min), 35–90% B (68–70 min), 90% B
(70–80 min), 90–5% B (80–81 min), and equilibrated in 5% B (81–100
min). The eluting peptide solution was automatically (online) electro-
sprayed into the mass spectrometer using a nanoelectrospray ion
source (Proxeon Biosystems, Odense, Denmark). The mass spec-
trometers were operated in positive ion mode and used in data-de-
pendent acquisition modes. A full scan (FT-MS) was acquired at a
target value of 1,000,000 ions with resolution r  60,000 over a mass
range of 335–1800 amu (atomic mass unit). The ten most intense ions
were selected for fragmentation in the LTQ Orbitrap Velos. Fragmen-
tation in the LTQ was induced by collision-induced dissociation (CID)
with a target value of 10,000 ions. For accurate mass measurement,
the “lock mass” function (lock mass  445.120036 Da) was enabled
for MS scan modes. To improve the fragmentation of phosphopep-
tides, the multistage activation algorithm in the Xcalibur software was
enabled for each MS/MS spectrum using the neutral loss values of
48.99, 32.66, and 24.50 m/z units. Former target ions selected for
MS/MS were dynamically excluded for 300 s. General mass spectro-
metric conditions were as follows: spray voltage, 1.0–2.5 kV; no
sheath and auxiliary gas flow; ion transfer tube temperature, 150–
180 °C; and normalized collision energy (35%) using wide band ac-
tivation mode for MS2. The isolation width was set to 2 amu for
IT-MS/MS. Ion selection thresholds were 600 counts for MS2. An
activation of q  0.25 and activation time of 30 ms were applied in
MS2 acquisitions. The fill time for FTMS was set to 1000 ms and for
ITMS to 150 ms. In this study, three independent biological replicates
of P14 wild-type versus PKD2 knockout CTLs were analyzed, with
two technical replicates for each biological sample (total 310 HPLC-
MS/MS runs). In two experiments, the wild-type cells comprised the
“light” condition, whereas the PKD2 knockout CTLs were labeled with
“heavy” amino acids (experiments 1 and 2). In the third experiment,
we performed a label switch (experiment 3).
Data Processing—For data analysis, we combined the raw data
obtained from the two technical replicates, the two subcellular frac-
tions (nucleus and cytosol), and the IMAC and TiO2 phosphopeptide
enrichment methods in each independent replicate. Data was pro-
cessed using MaxQuant (21) version 1.3.0.5 which incorporates the
Andromeda search engine (22). Proteins were mapped to the Uniprot
mouse protein database (“Mouse Complete Proteome“ retrieved on
August 19, 2013). This version of the database contains 16,618
mouse complete proteome entries (UniProtKB/Swiss-Prot canonical
and isoform sequence data). Search parameters specified an MS
tolerance of 20 ppm, an MS/MS tolerance at 0.5 Da and full trypsin
specificity, allowing for up to two missed cleavages. Carbamido-
methylation of cysteine was set as fixed modification and oxidation of
methionines, N-terminal protein acetylation, and phosphorylation of
serine, threonine, and tyrosine were set as variable modifications.
Peptides were required to be at least six amino acids in length with
false discovery rates (FDRs) of 0.01 calculated at the level of peptides,
proteins, and modification sites based on the number of hits against
the reversed sequence database.
To make our data accessible to the scientific community, the MS
proteomics data have been deposited to the ProteomeXchange Con-
sortium (http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository (23) with the data set identifier PXD001076. The
annotated_spectra.zip file contains .pdf files with annotated MS/MS
spectra for all PTM containing peptides described in the manuscript.
Separate MS/MS spectra for the highest identification and localiza-
tion scores have been deposited. To facilitate the search for the
annotated spectra, an additional excel file (Phospho (STY)Sites_an-
notated_spectra.xlsx file) containing a list of all reported sites and the
file names of their corresponding .pdf files have been deposited. Prior
to statistical analysis, the outputs from MaxQuant were filtered to
remove known contaminants and reverse sequences. The distribution
of SILAC ratios was normalized within MaxQuant at the peptide level
so that the median of log2 ratios is zero (21) (supplemental Table S1).
Bioinformatics and Statistical Tools—For functional pathway anal-
ysis, the different subsets of proteins identified in the data set were
subjected to functional analysis using DAVID bioinformatics re-
sources (24). Gene ontology terms for biological processes (BP) and
molecular functions (MF) charts were obtained using default statistical
parameters (threshold: count 2, ease 0.1). Proteins with protein kinase
activity and transcription factor activity were filtered based on
GOTERM_MF_FAT (GO:0004672 and GO:0003700, respectively).
For the kinase motif distribution, Linear Motif analysis tool in Per-
seus v1.4.1.3 software was used. Significance of PKD2 motif enrich-
ment was assessed by Chi-square test using Graphpad software
(http://www.graphpad.com/).
Western Blotting—Protein expression was assessed using stan-
dard Western blotting protocols described elsewhere (5). Blots were
probed with rabbit polyclonal anti-phospho-Cofilin-Ser3 and anti-Cofilin
(Cell Signaling Technology, Danvers, MA), a rabbit polyclonal antisera
recognizing HDAC7 (H-273, Santa Cruz Biotechnology, Santa Cruz,
CA), or a mouse monoclonal anti-Erk1/2 antibody (3A7, Cell Signaling
Technology) as indicated. Horseradish-peroxidase couple anti-rabbit
and anti-mouse antibodies were purchased from Jackson Immunore-
search, West Grove, PA.
Retroviral Transduction, Confocal Microscopy, and Flow Cytom-
etry—GFP-HDAC7 retrovirus was produced and P14 wild-type and
PKD2 deficient CTLs were transduced as described (17, 25). Cells
were adhered to coverslips coated with poly-l-lysine (Sigma-Aldrich),
then fixed for 30 min at 25 °C with 4% (w/v) paraformaldehyde. A
Zeiss LSM700 confocal microscope with an alpha Plan-FLUAR 100
objective (numerical aperture, 1.45) was used for confocal micros-
copy. For flow cytometry analysis, cells were stained as described (5).
Fluorescein isothiocyanate-anti-CD8 (clone 53–6.7), phycoerythrin-
anti-CD5 (clone 53–7.3) and allophycocianine-anti-CD25 (clone
PC61) were purchased from BD Pharmingen. Data were acquired on
a FACSCalibur (Becton Dickinson) and were analyzed with FlowJo
software (Treestar, Ashland, OR).
RESULTS
The CTL Phosphoproteome—The present screen used SI-
LAC-based quantitative phosphoproteomic analysis to char-
acterize the kinase-substrate signaling networks present in
antigen receptor activated cytotoxic T cells (CTL). SILAC la-
beling requires that cells undergo multiple cell doublings to
ensure sufficient label penetrance. Accordingly, for SILAC
experiments in CD8 T cells we used a well-characterized
model of CD8 CTL differentiation (17). In this model, antigen
primed CD8 T cells from P14 TCR transgenic mice are
cultured in interleukin 2 (IL-2) to produce a homogenous
population of fully differentiated effector CTL (20, 26, 27). This
model reproduces the in vivo situation where sustained IL-2
signaling promotes the production of terminally differentiated
effector CTLs required for virus clearance (28–30). The impact
of loss of the serine-threonine kinase PKD2 on CTL signaling
networks was also explored. Hence, in these experiments
wild-type or PKD2 knockout P14-TCR CTLs were differentially
labeled with one of two different isotope combinations of
lysine (K) and arginine (R), R0K0 (“light”) and R10K8 (“heavy”).
After 4 days of culture in SILAC media, wild-type and PKD2
knockout CTLs were mixed at equal cell number and triggered
via their TCR with cognate peptide for 5 min to maximally
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activate PKD2 in the wild-type population. Cells were then
lysed, digested with trypsin and phosphopeptides were en-
riched by HILIC fractionation followed by IMAC and TiO2
affinity chromatography. The workflow of our experiments is
displayed in Fig. 1A. The phosphopeptide-enriched fractions
were analyzed in a LTQ-Orbitrap Velos for mass spectrometry
(MS) data collection. All raw mass spectrometry data from
three biological replicates were processed using the Max-
Quant software.
A key aim of this study was to map the repertoire of protein
phosphorylations in CTLs. The collective analysis of the cur-
rent experiments identified and quantified 15,871 unique
phosphorylation sites in CTLs on 3505 distinct proteins. The
full list of all unique phosphosites identified in our analysis can
be found in supplemental Table S1. The ratio of phosphory-
lations on Serine, Threonine, and Tyrosine residues was 81/
17/2, comparable to what has been observed in other phos-
phoproteomic studies (31, 32). Importantly, the total number
of phosphosites identified in the individual biological repli-
cates was similar (Fig. 1B), and 58% of the unique phos-
phosites (9205 on 2767 proteins) were identified in all three
replicates (Fig. 1C). We have previously described a phospho-
proteomic analysis of CTLs but these earlier experiments only
identified 2000 phosphorylations in CTLs (17). The higher
coverage obtained in the present set of experiments offers a
more complete view of CTL signaling networks.
We used DAVID Bioinformatics Resources 6.7 (24) to per-
form functional pathway analysis on the phosphoproteins and
found that the CTL phosphoproteome is significantly overrep-
resented by proteins that control gene transcription and chro-
matin and by kinases and phosphatases that control protein
phosphorylation (Fig. 1D). There was also overrepresentation
in the CTL phosphoproteome of molecules that regulate mac-
romolecular catabolic processes, notably proteins that control
the ubiquitylation and sumoylation of proteins (Fig. 1D). The
mouse genome encodes over 500 protein kinases (33). The
present data detected phosphopeptides from 200 protein
kinases in CTLs (supplemental Table S2). We have also used
Linear Motif analysis tool in Perseus software to assign the
kinases most likely to phosphorylate the 15,871 phosphosites
identified in CTLs. This work indicated activity of a minimum
of 54 serine/threonine kinases and eight tyrosine kinases in
CTLs (Fig. 1E). One limitation of this latter analysis is that is
difficult to assign substrates individually to closely related
kinase isoforms that may share substrate specificity. For ex-
ample, a proportion of the identified phosphosites in CTLs
was predicted to be phosphorylated by Protein Kinase A
(PKA) or Protein Kinase C (PKC) (Fig. 1E). These are members
of the AGC family of kinases and it is very likely that sub-
strates assigned to PKA or PKC may in fact be phosphory-
lated by other AGC kinases. In this context, the present data
reveals the full repertoire of AGC kinase isoforms expressed in
CTLs. For example, five of the possible nine Protein Kinase C
isoforms were detected in CTLs, PKC , , PKC, and PKC
(Table I). The data presented in Table I show that AGC kinases
in CTL also include two of the four RSK isoforms, RSK1 and
RSK2; two of the three Akt isoforms, Akt1 and Akt2; one of the
three serum glucocorticoid kinases, SGK3, and one of the two
possible S6K isoforms, S6K1. In a similar way, the kinase
prediction analysis also indicated activity of the adenosine
monophosphate (AMP)-activated protein kinase in CTL (Fig.
1E). It is known that CTL are dependent for their survival on
LKB1 (34), which phosphorylates and activates AMPK1,
AMPK2, and 13 other AMPK-related kinases (AMPK-RK)
(35). The deletion of AMPK1 does not phenocopy the loss of
LKB1 in T cells indicating that it must be other AMPK family
members that mediate LKB1 actions (36). The present data
identify the candidates to mediate LKB1 function in T cells,
because CTLs express multiple AMPK family isoforms apart
from AMPK1 notably SNRK; SIK1 and 3, and MARK2, 3, and
4 (Table I). The data presented in Table I and supplemental
Table S2 identifying the specific kinase isoforms expressed in
CTLs offer invaluable knowledge in the context of the selec-
tion of isoform-specific inhibitors of kinase activity and the
development of new inhibitors targeting T-cell function.
The relevance of kinase-substrate networks present in
CTLs relies in their ability to dictate the transcriptional pro-
gram controlling T-cell effector function during an immune
response. Accordingly, the most overrepresented function
among phosphorylated proteins in CTLs is the regulation of
transcription (Fig. 1D). Of the 160 proteins with annotated
transcription factor activity identified in our data set (supple-
mental Table S3), we found relevant phosphorylation sites
that regulate transcriptional activity, subcellular localization,
and/or protein stabilization of essential transcription factors
for CTL development such as the STAT family members
STAT3, STAT4, and STAT5, Foxo1, Foxo3, or Myc (Table II).
More importantly, we identify phosphorylation sites in key
transcription factors such as Eomes, T-bet, Hif1, Arnt, Tfeb,
Srebf1, and Srebf2 or Irf4 whose function has not been yet
characterized (Table II). Notably, several of the phosphosites
found for these transcription factors are predicted to be phos-
phorylated by kinases known to be active in antigen stimu-
lated T cells such as Erk1/2, GSK3, or PKC family (Table II and
supplemental Table S3). These data thus open the door for
novel targeted approaches exploring the role of protein phos-
phorylation in regulating CTL transcriptional program.
Impact of PKD2 Deficiency on the Cytotoxic T-cell Phos-
phoproteome—A second aim of the present screen was to
use SILAC-based quantitative phosphoproteomic analysis to
explore the role of PKD2 in CTLs. The present data reveal that
antigen activated CTLs have high levels of active PKD2. We
found eight unique phosphosites derived from PKD2 in wild-
type CTLs including peptides corresponding to phosphory-
lated residue Ser711 (Table III). This phosphorylation is medi-
ated by PKCs and is critical for PKD2 catalytic activity (4).
When active, PKD2 autophosphorylates on Ser873 (37); the
presence of phosphorylated PKD2-Ser873 in CTLs thus con-
PKD2 Regulated Phosphoproteome in Cytotoxic T Cells
Molecular & Cellular Proteomics 13.12 3547
FIG. 1. Global phosphoproteomic analysis of PKD2 deficient CTLs. A, Experimental workflow. B, Number of unique phosphosites (p-site)
and number of distinct proteins identified and quantified in the three individual biological replicates. C, Percentage and numbers of unique
phosphosites (p-sites) identified in all three biological replicates. D, Graph represents the statistical significance (p value) of the biological
processes overrepresented within the CTL phosphoproteome. Inset numbers indicate number of proteins in each group. E, Pie chart represents
the frequency of kinases predicted to be active in CTLs.
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firms the activity of this kinase in these cells (Table III). Impor-
tantly, the SILAC ratio for all the phosphosites found for PKD2
was down-regulated in PKD2 deficient CTLs, particularly the
C-terminal phosphosites (Table III). Previous studies have
indicated that T cells do not express PKD1 and only express
low levels of PKD3 (4). The current analysis found six phos-
phopeptides for PKD3, and another four whose sequence can
be assigned to either PKD3 or PKD1. In addition, the data
shows that there was no change in the SILAC ratio for PKD3
phosphosites in PKD2 deficient CTLs (Table III). Thus, the loss
of PKD2 catalytic function in CTLs is not compensated by
increased expression or activity of other PKD isoforms.
The PKD2 deficient mice used in the present study were
generated by a retrovirus-based gene-trap technique, where
the “gene-trap” insertion within the Prkd2 locus was mapped
to exon 15 encoding from amino acid 658 of PKD2 (4). PKD2
antibodies raised against the C-terminal portion of the protein
(exons 16–18) have thus confirmed the loss of PKD catalytic
activity in PKD2 “gene-trap” mice (4), but the possibility that a
truncated N-terminal noncatalytic fragment of PKD2 protein
might be expressed in the PKD2 “gene-trap” T cells has not
been considered. The present data also show that phospho-
sites from the C terminus of PKD2 were down-regulated by
more than 14-fold in the PKD2 “gene-trap,” indicating that
they are absent (Table III). However, phosphosites derived
from the N terminus of PKD2 (S197, S198, S200, S211, and
S212) showed a two- to threefold decrease in expression in
PKD2 gene trap CTLs. These data argue that PKD2 “gene-
trap” T cells still express a low level of a residual N-terminal
fragment of PKD2 and confirm that they lack the PKD2 cata-
lytic domain.
TABLE I
AGC family and AMPK related kinases in CTLs. List of AGC and
AMPK-related kinase family members identified in the CTL
phosphoproteome
Kinase family Kinase
Isoforms
present in CTLs
AGC PDK1 PDK1/Pdpk1
PKC PKC/Prkca
PKCb/Prkcb
PKC/Prkcq
PKC/Prkch
PKC/Prkcd
PKN PNK1/Pnk1
PNK2/Pnk2
Akt Akt1/Akt1
Akt2/Akt2
S6K S6K1/Rps6kb1
RSK RSK1/Rps6ka1
RSK2/Rps6ka3
SGK SGK3/Sgk3
PKA PKAa/Prkaca
PKAb/Prkacb
MSK Msk1/Rps6ka5
Msk2/Rps6ka4
AMPK related kinases AMPK AMPKa1/Prkaa1
SNRK SNRK/Snrk
SIK SIK1/Sik1
SIK3/Sik3
MARK MARK2/Mark2
MARK3/Mark3
MARK4/Mark4
TABLE II
Phosphosites in relevant CTL transcription factors. Identified phos-
phosites in selected transcription factors known to be essential for
CTLs differentiation and function, presented as gene name and mod-
ified position (Mod. Pos.)
Gene name Mod. Pos.
Stat3 S701; Y705; T714; T716; S727
Stat4 S714; S716; S722; S714; S716; S722
Stat5a S127; S128; Y694; S773; S779; S791
Stat5b S127; S128; Y699; S127; S128; Y699
Foxo1 S253; S284; S287; S295; S326; T330;
S429; T464; S465; S467
Foxo3 S7; S12; S252; T260; S279; S285;
S293; S296; S424
Myc T58; S62; S64; S71; S73; Y74; S160;
S164; S282; S288; S293
Eomes S52; S117; S617; S667; S672; S676
Tbx21 S498; S506; S508; S514
Hif1a S450; S679
Arnt S45; S77; S82; S83
Tfeb S108; S113; S121; S333; S465; S466
Srebf1 S96; S100
Srebf2 S458
Irf4 S186; T435; T436; S446; S447
TABLE III
PKD2 and PKD3 phosphosites. List of phosphosites derived from
PKD isoforms detected in CTL phosphoproteome, presented as gene
name, modified position (Mod. Pos.), sequence window (Seq. win-
dow) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the
three biological replicates)
Gene name Mod. Pos. Seq. window KO/WT ratio
PKD2
Prkd2 S197 ARKRRLSSTSLAS 0.67
S198 RKRRLSSTSLASG 0.43
S200 RRLSSTSLASGHS 0.48
S211 HSVRLGSSESLPC 0.36
S212 SVRLGSSESLPCT 0.63
S214 RLGSSESLPCTAE 0.18
S711 EKSFRRSVVGTPA 0.11
S873 GLAERISIL___ 0.06
PKD3
Prkd3 S31 APSPCSSPKTGLS 1.37
S27 AVLPAPSPCSSPK 1.26
S30 PAPSPCSSPKTGL 1.17
S213 VRKRRLSNVSLPG 1.06
S216 RRLSNVSLPGPGL 1.06
S252 PSKRIPSWSGRPI 0.96
Prkd3;Prkd1 S391 ETVKTISPSTSNN 1.07
S395 TISPSTSNNIPLM 0.97
S730 RIIGEKSFRRSVV 0.79
S734 EKSFRRSVVGTPA 0.79
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As mentioned above, CTL effector function is maintained by
the integration of signals emanating from the TCR and the
IL-2R. The SILAC ratio of wild-type and PKD2 deficient cells
comparison displayed a normal distribution (Fig. 2A), suggest-
ing that deletion of PKD2 did not skew the CTL phosphopro-
teome. In particular, there was not a general decrease in TCR
regulated phosphorylations in PKD2 null cells. For instance,
TCR triggering elevates intracellular calcium levels and in-
duces calcium/calcineurin-regulated dephosphorylation of
the transcription factor Nuclear Factor of Activated T cells c2
isoform (NFATc2) (17). PKD2 loss had no impact on NFATc2
phosphorylation (Table IV). There was also no evidence for
loss of TCR mediated phosphorylation of the microtubule
stabilizing protein Stathmin (Stmn1) on residues that are
phosphorylated by Calcium/Calmodulin dependent kinase IV
(Table IV). Moreover, triggering of the TCR phosphorylates
AMPK1 on Thr172 via a [Ca2]i-CaMKK pathway and AMPK
Thr172 phosphorylation was normal in PKD2 null T cells (cor-
responding to Prkaa1-Thr183 in our data set, Table IV). It was
also notable that the phosphorylation and activity of Erk1 and
2 was not influenced by PKD2 loss (Mapk3 and Mapk1, re-
spectively, Table IV). IL-2R signaling in CTLs induces high
levels of active Akt and we noted normal levels of phosphor-
ylated Akt substrate sites Ser253/Ser252 in Foxo1/3 respec-
tively, indicating that Akt activity was normal in PKD2 null CTL
(Table V). Moreover, IL-2 controls the tyrosine and serine
phosphorylation of the transcription factors STAT3, STAT5a,
and STAT5b in T cells (38, 39). These transcription factors
were normally tyrosine and serine phosphorylated in PKD2
null CTL (Table V). Collectively, data in Table IV and V show
that many CTL signaling pathways function normally in the
absence of PKD2 catalytic function.
PKD2 Regulated Phosphorylations in CTL—There was
some impact of PKD2 loss on the CTL phosphoproteome.
Hence, of the 15,871 unique phosphosites identified and
quantified in CTLs, 450 phosphosites on 281 distinct proteins
were down-regulated and 300 phosphosites on 196 proteins
were up-regulated in PKD2 null CTLs (Fig. 2B). The threshold
for change was set to a z-core of 2 for phosphorylation ratios
in PKD2 null versus wild-type CTLs, using the averaged value
of the three biological replicates (1.8-fold change). We dis-
carded phosphorylation events that displayed an inconsistent
trend in regulation among the three biological replicates (i.e.
down-regulated in one replicate and up-regulated in another).
Based on this threshold, the data showed that PKD2 directly
and indirectly regulates about 5% of the phosphorylations of
cytotoxic T cells, on proteins that are mainly involved in tran-
scription, chromosome reorganization and more importantly
in the context of cytotoxic T cells, in leukocyte activation and
hemopoiesis (Fig. 2C).
Among the down-regulated sites implicated in leukocyte
activation we found five phosphosites derived from CD5 (Fig.
2D), a cell surface glycoprotein whose expression is normally
increased after activation in T cells (40). This could reflect loss
of CD5 phosphorylation or loss of CD5 expression. In this
respect we have established that PKD2 controls expression of
CD5 during T-cell development (15) but its role in controlling
CD5 expression in peripheral T cells is unknown. Accordingly,
we used flow cytometry to examine if CD5 expression was
impaired in PKD2 deficient CTLs. Data in Fig. 2E show that
PKD2 deficient CTLs express lower levels of CD5 than their
wild-type counterparts.
We also found two down-regulated phosphosites derived
from the F-actin severing protein Cofilin, Ser3, and Ser41, in
the TCR activated PKD2 null CTL (Fig. 2F). This result was
initially surprising as previous studies have shown that TCR
triggering, which activates PKD2, normally down-regulates
Cofilin-Ser3 phosphorylation (17). Indeed, Western blot ex-
periments confirmed that TCR triggering reduces Cofilin-Ser3
phosphorylation in CTLs (Fig. 2G). Nevertheless, there was
strikingly less phosphorylated Cofilin-Ser3 in the both non-
stimulated and TCR stimulated PKD2 null T cells compared
with wild-type cells (Fig. 2G). These data orthogonally vali-
dated the reduced Cofilin-Ser3 phosphorylation in the TCR
activated PKD2 null T cells observed in the mass spectrom-
etry experiments (Fig. 2F, G). The reduced Cofilin phosphor-
ylation in PKD2 null T cells argues that PKD might control the
activity of kinase pathways upstream Cofilin phosphorylation.
In this respect, previous studies have reported a PKD require-
ment for the phosphorylation of Ser3 on Cofilin via PKD acti-
vation of PAK4/LIMK (41, 42).
To search for PKD2 substrate candidates within the data
set we used the following criteria: the SILAC ratio must be
down-regulated in the PKD2 null cells, and the sequence of
the down-regulated phosphosite must correspond to a PKD2
consensus motif. The consensus sequence for PKD2 phos-
phorylation described in the literature is (L/V/I)x(R/K)xx(S*/T*)
(43–45). In addition to the described consensus site, PKD2
has an auto-phosphorylation site at residue Ser873 (Ser916 in
PKD1) (37). This PKD2 autophosphorylation motif has slightly
modified sequence compared with the conventional motif,
(L/I)xx(R/K)x(S*/T*), but because it is a well described sub-
strate for PKD2 we have included this sequence in our search
for PKD2 phosphorylation sites. The analysis of the whole
data set determined that among the 15,871 phosphosites
found in our study, 940 contained a consensus motif for PKD2
phosphorylation (6% of the data set) (supplemental Table S1).
Strikingly, 73 out of the 450 phosphosites (16%) with de-
creased phosphorylation in PKD2 deficient CTLs had a PKD2
consensus motif, whereas only 26 out of the 300 phospho-
sites (9%) with increased phosphorylation matched the PKD2
consensus motif (Fig. 2H). Thus among the down-regulated
phosphosites in PKD2 knockout CTLs, we had a significant
enrichment of phosphosites containing a consensus phos-
phorylation site for PKD2 (p  0.0001, Fig. 2I). Detailed infor-
mation about modified position and ratios of the 73 phospho-
sites on 69 distinct proteins down-regulated in our data
set that had a PKD2 consensus motif can be found in
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FIG. 2. Impact of loss of PKD2 in the CTL phosphoproteome. A, Histogram shows the SILAC ratio distribution of the data set, using the
averaged SILAC ratio of the three biological replicates (PKD2 knockout versus wild-type, AVG KO/WT, log2 value). B, Graph shows SILAC ratio
distribution (AVG KO/WT, log2 value) plotted against the signal intensity (sum of intensities of the three biological replicates, log10) for all
identified phosphopeptides. Dark dots and inset numbers indicate phosphosites (p-sites) with a z-score of 2 (1.8-fold change). C, Graph
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supplemental Table S4. It was notable that 377 of the 450
phosphosites with decreased phosphorylation in PKD2 defi-
cient CTLs, including Cofilin1-Ser3 (Fig. 2E), did not have a
consensus PKD2 site and hence are unlikely to be directly
phosphorylated by PKD2 (Fig. 2B, 2F). In addition, loss of
PKD2 increased the phosphorylation of 300 phosphosites
(Fig. 2B) and this is clearly an indirect consequence of PKD2
loss.
Table VI lists the 69 proteins phosphorylated on a PKD2
consensus sequence whose phosphorylation was decreased
in PKD2 null T cells. It also lists the biological function as-
cribed to these proteins. The decreased phosphorylation of
these proteins in PKD2 null cells could reflect that they are
direct substrates for PKD2. However, it is possible that the
expression of the protein is decreased. To attempt discrimi-
nate between these possibilities, we analyzed all the phos-
phosites found in our study for the proteins presented in Table
VI. For 41 proteins we could find evidence that although they
had lost phosphorylation on PKD consensus sequences there
were other phosphorylation sites that were unchanged, indi-
cating that the protein expression was not decreased. For 22
proteins only one to two phosphosites were found and hence
we cannot make any conclusion about their expression. How-
ever, for another four proteins, HDAC7, Osbl3, Sgk223, and
Specc1, there was decreased phosphorylation of all detected
peptides derived from these proteins (supplemental Table
S1). This could indicate that there is lower expression of these
proteins in PKD2 deficient CTLs. This second group included
histone deacetylase HDAC7 (Table VI), which is a well char-
acterized PKD substrate in many cells including B cells (12,
46). Moreover, in CTLs, HDAC7 phosphorylation on PKD con-
sensus sites is essential for HDAC7 nuclear exclusion (17).
HDAC7 is thus a very strong candidate for a PKD2 substrate
in CTLs. However, Fig. 3A shows that the loss HDAC7 phos-
phorylation in PKD2 null CTLs occurred on multiple sites and
was not restricted to the PKD substrate sequences Ser156
and Ser182 (47, 48). We therefore explored the possibility that
PKD2 knockout CTLs may have decreased expression of
HDAC7. The Western blot in Fig. 3B addresses this question
and shows that PKD2 knockout CTLs express lower levels of
HDAC7 compared with wild-type CTLs. The decrease in
HDAC7 phosphorylation in PKD2 null CTL thus reflects that
these cells have reduced expression of this molecule. In this
respect, nonphosphorylated HDAC7 would accumulate in the
nucleus whereas phosphorylated HDAC7 is in the cytosol
(17). Confocal microscopy comparing the intracellular location
of HDAC7 in wild-type and PKD2 deficient CTLs clearly
showed that HDAC7 localization is mainly cytosolic in both
wild-type and PKD2-deficient CTLs (Fig. 3C). HDAC7 phos-
phorylation on PKD consensus sites is also essential for CTL
to express the IL-2Ralpha chain (CD25) (17). Fig. 3D shows
that PKD2 deficient cells express normal levels of CD25.
These data collectively argue that HDAC7 is not a PKD2
substrate in cytotoxic T cells.
represents the statistical significance (p value) of the biological processes overrepresented among the proteins with down-regulated and
up-regulated phosphosites in PKD2 deficient CTLs. Inset numbers indicate number of proteins in each group. D, Phosphosites derived from
CD5 (Cd5), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological
replicates). E, Flow cytometry analysis of CD5 cell surface expression in P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO)
CTLs. F, Phosphosites derived from Cofilin (Cfl1), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT
ratio, averaged value of the three biological replicates).G, Western blot analysis of wild-type and PKD2 knockout (WT and PKD2-KO) CTLs after
5 min of antigen receptor stimulation (TCR), using anti-phospho-Cofilin-Ser3 and anti-Cofilin antibodies. H, Graph shows SILAC ratio
distribution plotted as in 2B for all identified phosphopeptides. Dark dots and inset number indicate phosphosites with at least 1.8-fold
down-regulation that contain a PKD2 consensus motif (PKD2 motif). I, Frequency of PKD2 consensus motifs among all, up- and down-
regulated phosphopeptides. Asterisks indicate significance of PKD2 motif enrichment (***  p  0.0001, Chi-square test).
TABLE IV
T-cell receptor regulated phosphosites. Selected phosphosites
known to change phosphorylation status after TCR stimulation, pre-
sented as gene name, modified position (Mod. Pos.) and SILAC ratio
KO/WT (KO/WT ratio, averaged value of the three biological
replicates)
Gene name Mod. Pos. KO/WT ratio
Nfatc2 S136 0.99
S238 0.74
S270 0.50
S365 1.40
S369 1.53
S757 0.98
Stmn1 S16 0.90
S25 0.92
S38 0.82
S63 0.93
Prkaa1 T183 1.04
Mapk3 T203 1.18
Mapk1 T179 1.00
T183 0.99
TABLE V
Interleukin 2 regulated phosphosites. Selected phosphosites known
to change phosphorylation status after IL-2 stimulation, presented as
in Table IV
Gene name Mod. Pos. KO/WT ratio
Stat3 Y705 1.73
S727 1.33
Stat5a Y694 0.88
S779 1.24
Stat5b Y699 0.90
Akt1 S473 0.82
Akt2 S474 0.96
Foxo1 S253 0.98
Foxo3 S252 0.97
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The data presented for HDAC7 is thus a good demonstra-
tion of how decreased phosphorylation of a protein in a par-
ticular cell may be because of the fact its expression is de-
creased. Nevertheless, in the current data set there were at
least 41 proteins that had decreased phosphorylation on PKD
substrate sequences yet phosphorylations on other sites were
unchanged, making these strong candidates to be PKD2 sub-
strates (Table VII). Six of these proteins, Hip1r, Map4, Rdbp,
Ssr3, Snx2, and Pcbp1, have been shown to be in vitro
substrates for PKD1 (19) (Tables VI and VII). We also identified
Rin3 (Ras and Rab interactor 3) as a PKD2 substrate (Tables
VI and VII) and previous studies have identified Rin1 as a
PKD1 substrate in fibroblasts (49). It was, however, important
that our studies identified novel PKD2 substrate candidates in
CTLs such the E3 ubiquitin ligase c-Cbl (Cbl) (50), the Lysine
(K)-specific demethylase 2a (Kdm2a) (51), the transcription
factor NFAT3 (52) and the Phosphorylated adaptor for RNA
export (Phax), a regulator of U snRNA nuclear export (53).
DISCUSSION
The present study explores the phosphoproteome of anti-
gen receptor activated cytotoxic T lymphocytes and identifies
15,871 unique phosphorylation sites on 3505 distinct proteins
in this critical lymphocyte population. This is a unique data set
about the kinase-substrate signaling networks in CTL that
allows new insights about the repertoire of protein kinases
that are expressed and active in T cells. One new vision
derived from this work is that the CTL phosphoproteome was
overrepresented by proteins that regulate macromolecular
catabolic processes, notably proteins that control the ubiqui-
tylation and sumoylation. In this respect, the reversible ubiq-
uitin or sumo modification of proteins is critical for intracellular
signal transduction pathways (54, 55). Moreover, it has been
recognized for several years that cross talk between phos-
phorylation and ubiquitylation/sumoylation signaling occurs
(56, 57). For example, phosphorylation of various E3 ligases
can either positively or negatively regulate their deubiquityla-
tion activity (56). The phosphorylation of a protein can create
a docking site for a particular E3 ligase whereas in other
cases, phosphorylation controls the intracellular localization
of E3 ligases and their substrates (56). The full extent of the
cross talk between protein phosphorylation and ubiquitylation
is not understood in any cell system. However, the over-
representation in the CTL phosphoproteome of molecules
linked to the control of ubiquitylation and sumoylation signal-
ing is a striking indication that the intersection between dif-
ferent post-transcriptional modifications may be critical to
control CTL function.
The study also presents an exhaustive analysis of the im-
pact of the loss of a single kinase, PKD2, in CTLs using an
unbiased phosphoproteomic approach. This global analysis
allows the characterization of direct and indirect PKD2-regu-
TABLE VI
Functional annotation of PKD2 substrate candidates. 73 PKD2 substrate candidates involved in the indicated cellular functions were categorized
based on available literature
Intracellular transport
Lymphocyte signaling
Small GTPase regulators Cytoskeleton regulation Endocytosis Golgi function
Arhgap11a Arhgef2 Akap10 Dennd5a Casp8ap2
Arhgef2 Arpc1b Arl14ep Lrmp Cbl
Kifap3 Lpp Cbl Osbpl3 Hsh2d
Rin3 Map4 Hip1r Ssr3 Ikbke
Tsc2 Ndrg1 Kifap3 Inpp4b
Ospl3 Ndrg1 Ndrg1
Plec Reps1 Plekha2
Rin3 Snx2 Prrc2a
Tjp3 Snx9 Ptpn22
Vim Tbc1d5 Sgk223
Wnk1 Ube2o Tsc2
Vps26b
Gene expression
Other functions
Chromatin regulation Transcription Translation Ubiquitin ligases
Arid4b Casp8ap2 Bud13 Cbl Ccdc92
Arid5b Lpp Farsa Dcaf5 Dmwd
Hdac5 Lrrfip1 Nup214 Rnf213 Dnajc8
Hdac7 Nfatc3 Pcbp1 Ube2o Fam76b
Kansl3 Pola2 Phax Specc1
Kdm2a Polk Rpl19
Setdb1 Rdbp Sugp2
Sfr1 Supt16h
Trim28
Ylpm1
Znf280d
Zfp687
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lated phosphorylation events. CTL express a minimum of 200
kinases yet the loss of a single kinase can have complex
direct and indirect effects on the phosphoproteome. A single
kinase PKD2 thus directly and indirectly regulates about 5%
of CTL phosphorylations. Proteins identified as PKD2 sub-
strates in CTLs include proteins involved in two distinct bio-
logical functions: regulation of intracellular protein trafficking
and control of different aspects of gene expression. In the
context of vesicular trafficking, the proteins phosphorylated
by PKD2 in CTLs include a number of Rab GTPases regula-
tors such as Akap10 (58), Tbc1d5 (59), and Rin3 (60), or
Sorting nexin 2 (Snx2) (59), which contains a phosphoinositide
binding domain. Notably, the relocalization of intracellular
vesicles containing signaling molecules has been shown to be
required for antigen receptor signal propagation in T cells (61,
62). Future experiments will determine if PKD2-regulated
phosphorylations influence the amplitude, location, and dura-
tion of T-cell signaling by controlling intracellular vesicle traf-
ficking. Interestingly, among the PKD2 substrate candidates
we also find GEF-H1 (Arhgef2), a microtubule-associated
guanine nucleotide exchange factor whose function has been
recently shown to be crucial for antiviral host defenses (63). In
the context of phosphorylation and ubiquitylation crosstalk
mentioned above, our study identified the E2 ubiquitin conju-
gating enzyme Ube2o which has a crucial role in endosomal
protein trafficking (64) as novel PKD2 substrate in CTLs.
Moreover the identification of the E3 ligase c-Cbl as a PKD2
substrate is also interesting, because c-Cbl is known to reg-
ulate the function and intracellular trafficking of several mol-
ecules implicated in antigen receptor signaling (50). Future
studies into the role of PKD2 in regulating endosomal protein
trafficking in CTLs may thus be interest.
Previous studies have shown that PKD2 has a critical role to
control the T-cell transcriptional program. Antigen stimulation
in CD8 T cells induces changes in the expression levels of
2600 annotated genes and PKD2 both positively and neg-
atively regulates expression of 5% this transcriptional pro-
gram (5). Here we have identified PKD2 substrate candi-
dates implicated in regulation of transcription and
translation such as the Lysine (K)-specific demethylase 2a
(Kdm2a) (51), the transcription factor NFAT3 (52) and Phax
(53), a protein that controls mRNA export from the nucleus.
However, the diversity of the PKD2 controlled phosphopro-
teome identified herein affords an explanation for the broad
role of PKD2 as a regulator of the T-cell transcriptional
program. Thus, there is no evidence for a simple linear
pathway of phosphorylation of a single substrate that ex-
FIG. 3. Analysis of HDAC7 phosphorylation, expression and function in PKD2 deficient CTLs. A, Phosphosites derived from HDAC7
(Hdac7), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological
replicates). B, Western blot analysis of three sets of wild-type and PKD2 knockout (WT and PKD2-KO) CTLs using an anti-HDAC7 antibody.
Anti-Erk1 antibody was used as a control of equal loading. C, Microscopy analysis of the subcellular distribution of GFP-HDAC7 in retrovirally
transduced P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO) CTLs. Original magnification, 100. D, Flow cytometry
analysis of CD25 cell surface expression in P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO) CTLs.
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plains PKD2 action. Rather, the impact of PKD2 loss will
thus result from a complex interplay between the direct and
indirect effects of PKD2 loss on the phosphoproteome that
are exposed by the present work.
A small number of the PKD2 substrates identified herein
have been shown to be substrates for PKD family kinases in
other cell lineages (Hip1r, Map4, Rdbp, Ssr3, Snx2, and
Pcbp1). However, it is of equal importance to note that some
of the key PKD substrates identified in experiments in fibro-
blasts, endothelial, and epithelial cells are not substrates in T
cells. HDAC7 is thus a PKD substrate in many cells but not in
CTLs, the protein phosphatase Slingshot (SSH1) is phosphor-
ylated on Ser929 by PKD in HeLa and breast adenocarcinoma
cell lines (6, 7) whereas the present data set revealed that
SSH1 was phosphorylated on Ser929 in CTLs but
this phosphorylation was not reduced on PKD2 null CTLs
(supplemental Table S1). In the context of intracellular protein
transport and Golgi function, other well described PKD sub-
strates are the phosphatidylinositol-4 kinase III beta; a regu-
lator of Golgi vesicle fission and protein secretion (9) and the
lipid and sterol transfer proteins CERT and OSBP (10, 11). The
present data identified eight unique phosphosites on phos-
phatidylinositol-4 kinase III beta (Pi4kb) including the Ser294,
the PKD site previously characterized by Hausser and col-
TABLE VII
PKD2 substrate candidates phosphosites. List of phosphosites from selected PKD2 substrate candidates, presented as gene name, protein
name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates)
Gene name Protein name Mod. Pos. KO/WT Ratio
Akap10 A-kinase anchor protein 10, mitochondrial S257 0.47
Arhgap11a Rho GTPase-activating protein 11A S847 0.51
Arhgef2 Rho guanine nucleotide exchange factor 2 S718 0.57
Arid4b AT-rich interactive domain-containing protein 4B S473 0.42
Arid5b AT-rich interactive domain-containing protein 5B S1002 0.20
Bud13 BUD13 homolog S18 0.39
Casp8ap2 CASP8-associated protein 2 S1220 0.48
Cbl E3 ubiquitin-protein ligase CBL S617 0.57
Ccdc92 Coiled-coil domain-containing protein 92 S308 0.40
Dcaf5 DDB1- and CUL4-associated factor 5 S790 0.11
Dennd5a DENN domain-containing protein 5A S193 0.47
Dmwd Dystrophia myotonica WD repeat-containing protein T453 0.38
Fam76b Protein FAM76B S227 0.18
Hip1r Huntingtin-interacting protein 1-related protein S1045 0.13
Inpp4b Type II inositol 3,4-bisphosphate 4-phosphatase S470 0.23
Kansl3 KAT8 regulatory NSL complex subunit 3 S631 0.43
Kdm2a Lysine-specific demethylase 2A S422 0.29
Lrmp Lymphoid-restricted membrane protein S346 0.55
Lrrfip1 Leucine-rich repeat flightless-interacting protein 1 S284 0.56
Map4 Microtubule-associated protein 4 S973 0.48
Nfatc3 Nuclear factor of activated T-cells, cytoplasmic 3 S416 0.54
Nup214 Nuclear pore complex protein Nup214 S1029 0.37
Pcbp1 Poly(rC)-binding protein 1 S246 0.52
Phax Phosphorylated adapter RNA export protein S155 0.41
Plekha2 Pleckstrin homology domain-containing family A member 2 S349 0.45
Pola2 DNA polymerase alpha subunit B S126 0.38
Prrc2a Protein PRRC2A S166 0.44
Ptpn22 Tyrosine-protein phosphatase non-receptor type 22 S452 0.52
Rdbp Negative elongation factor E S37 0.21
Reps1 RalBP1-associated Eps domain-containing protein 1 S475 0.50
Rin3 Ras and Rab interactor 3 S389 0.39
Rnf213 E3 ubiquitin-protein ligase RNF213 S4603 0.27
Sfr1 Swi5-dependent recombination DNA repair protein 1 homolog S139 0.22
Snx2 Sorting nexin-2 S226 0.38
Supt16h FACT complex subunit SPT16 S650 0.57
Tbc1d5 TBC1 domain family member 5 S546 0.45
Tsc2 Isoform E of Tuberin S1254 0.52
Ube2o Ubiquitin-conjugating enzyme E2 O S394 0.40
Vps26b Vacuolar protein sorting-associated protein 26B S304 0.40
Wnk1 Serine/threonine-protein kinase WNK1 S2625 0.49
Znf687 Zinc finger protein 687 S1118 0.18
Znf687 Zinc finger protein 687 S495 0.43
Znf687 Zinc finger protein 687 S351 0.54
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leagues in fibroblast (9). We found that there was no repro-
ducible loss of the phosphorylation of Phosphatidylinositol-4
kinase III beta in PKD2 null cells. Similarly, the ceramide
transfer protein CERT (Col4a3bp) has been shown to be
phosphorylated on Ser132 by PKD, thereby reducing its cer-
amide transfer activity and placing PKD as a regulator of lipid
homeostasis. The phosphorylation of CERT of Ser132 was not
reproducibly lost in PKD2 null CTLs making this an unlikely
PKD2 substrate in CTLs.
Collectively, the data presented here show that PKD family
kinases have both common and unique functions in different
cell lineages. One explanation for this variability in substrates
for different PKD isoforms could be that PKDs show cell
lineage specific patterns of intracellular localization. For ex-
ample in HEK293 and Hela cells PKD isoforms localize to the
trans-Golgi network, where PKD phosphorylates substrates
such as phosphatidylinositol-4 kinase III beta (9), CERT, and
OSBP (10, 11). PKD1 has been also shown to be recruited to
the lamellipodium in HEK293 cells and pancreatic tumor cell
lines, where PKD phosphorylates substrates such as SSH1 (6,
7), cortactin (65), or Rin1 (8). In contrast, active PKD is mainly
cytosolic in T cells (2). PKD is briefly recruited to the plasma
membrane after antigen receptor stimulation but rapidly re-
turns to the cytosol where it remains active (2). Thus, the
cytosolic localization of PKD2 in T cells may prevent the
access to substrates in particular cell compartments such as
the Golgi network or the plasma membrane.
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